Correlation Engine 2.0
Clear Search sequence regions

  • bad prognosis (1)
  • help (1)
  • humans (1)
  • LDH (7)
  • patients (3)
  • prognosis (1)
  • tumour burden (2)
  • Sizes of these terms reflect their relevance to your search.

    Immunotherapies have significantly improved the survival of patients in many cancers over the last decade. However, primary and secondary resistances are encountered in most patients. Unravelling resistance mechanisms to cancer immunotherapies is an area of active investigation. Elevated levels of circulating enzyme lactate dehydrogenase (LDH) have been historically considered in oncology as a marker of bad prognosis, usually attributed to elevated tumour burden and cancer metabolism. Recent evidence suggests that elevated LDH levels could be independent from tumour burden and contain a negative predictive value, which could help in guiding treatment strategies in immuno-oncology. In this review, we decipher the rationale supporting the potential of LDH-targeted therapeutic strategies to tackle the direct immunosuppressive effects of LDH on a wide range of immune cells, and enhance the survival of patients treated with cancer immunotherapies. Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.


    Tina B S Miholjcic, Heloise Halse, Mélodie Bonvalet, Amélie Bigorgne, Mathieu Rouanne, Laurent Dercle, Vishnu Shankar, Aurélien Marabelle. Rationale for LDH-targeted cancer immunotherapy. European journal of cancer (Oxford, England : 1990). 2023 Mar;181:166-178

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 36657325

    View Full Text